Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1118)	4/16/2002 10:03:22 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

So, what have they got? (an analysis worth doing, given the cash to MC ratio, regardless that the cash is a long-term loan) Time on the learning curve, delivering small molecules to the lung. Time on the small molecule clinical learning curve, HCV patients. A potent RSV-spcific molecule where FDA has apparently said "make a phase I work in infants". The analysis by Cacaito in the VPHM thread is sufficient here. It's another tough indication to bite off. 50406 "backups" for HCV, one of which is scheduled for the clinic within eight months. We know that Wyeth/VPHM have studied at least two target molecules. A respected group of chemists that has proven that they can produce potent anti-virals. pleconaril, which FDA may still want available for compassionate use (immunosuppressed kids, etc.). VP68881, and a marked appreciation for how NOT to test it. Oodles of cash, and a serious issue with depression. Can anyone add to the list?